Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.16
INSV's Cash to Debt is ranked lower than
89% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.35 vs. INSV: 0.16 )
Ranked among companies with meaningful Cash to Debt only.
INSV' s 10-Year Cash to Debt Range
Min: 0.09  Med: 9.96 Max: No Debt
Current: 0.16
Equity to Asset -3.14
INSV's Equity to Asset is ranked lower than
100% of the 575 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. INSV: -3.14 )
Ranked among companies with meaningful Equity to Asset only.
INSV' s 10-Year Equity to Asset Range
Min: -5.91  Med: -0.24 Max: 0.95
Current: -3.14
-5.91
0.95
F-Score: 4
Z-Score: -65.89
M-Score: -4.89
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -276.54
INSV's Operating margin (%) is ranked lower than
92% of the 669 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.92 vs. INSV: -276.54 )
Ranked among companies with meaningful Operating margin (%) only.
INSV' s 10-Year Operating margin (%) Range
Min: -889900  Med: -97.23 Max: 42.52
Current: -276.54
-889900
42.52
Net-margin (%) -294.04
INSV's Net-margin (%) is ranked lower than
93% of the 671 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.96 vs. INSV: -294.04 )
Ranked among companies with meaningful Net-margin (%) only.
INSV' s 10-Year Net-margin (%) Range
Min: -860000  Med: -155.48 Max: 325.8
Current: -294.04
-860000
325.8
ROA (%) -314.14
INSV's ROA (%) is ranked lower than
99% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. INSV: -314.14 )
Ranked among companies with meaningful ROA (%) only.
INSV' s 10-Year ROA (%) Range
Min: -441.9  Med: -61.55 Max: 280.66
Current: -314.14
-441.9
280.66
ROC (Joel Greenblatt) (%) -776.45
INSV's ROC (Joel Greenblatt) (%) is ranked lower than
90% of the 714 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.24 vs. INSV: -776.45 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
INSV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8660.97  Med: -545.95 Max: 1512.94
Current: -776.45
-8660.97
1512.94
Revenue Growth (3Y)(%) -24.60
INSV's Revenue Growth (3Y)(%) is ranked lower than
93% of the 548 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. INSV: -24.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
INSV' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -61.80 Max: 188.4
Current: -24.6
0
188.4
» INSV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with INSV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 9.89
INSV's P/S is ranked lower than
78% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.08 vs. INSV: 9.89 )
Ranked among companies with meaningful P/S only.
INSV' s 10-Year P/S Range
Min: 0.55  Med: 3.61 Max: 269
Current: 9.89
0.55
269
Current Ratio 0.18
INSV's Current Ratio is ranked lower than
99% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. INSV: 0.18 )
Ranked among companies with meaningful Current Ratio only.
INSV' s 10-Year Current Ratio Range
Min: 0.06  Med: 2.94 Max: 16.2
Current: 0.18
0.06
16.2
Quick Ratio 0.18
INSV's Quick Ratio is ranked lower than
99% of the 618 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.68 vs. INSV: 0.18 )
Ranked among companies with meaningful Quick Ratio only.
INSV' s 10-Year Quick Ratio Range
Min: 0.05  Med: 2.94 Max: 16.2
Current: 0.18
0.05
16.2
Days Sales Outstanding 29.09
INSV's Days Sales Outstanding is ranked higher than
85% of the 601 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.80 vs. INSV: 29.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
INSV' s 10-Year Days Sales Outstanding Range
Min: 11.04  Med: 45.63 Max: 116.86
Current: 29.09
11.04
116.86

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 3.09
INSV's Price/Median PS Value is ranked lower than
83% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.26 vs. INSV: 3.09 )
Ranked among companies with meaningful Price/Median PS Value only.
INSV' s 10-Year Price/Median PS Value Range
Min: 0.22  Med: 1.88 Max: 52.27
Current: 3.09
0.22
52.27
Earnings Yield (Greenblatt) (%) -22.76
INSV's Earnings Yield (Greenblatt) (%) is ranked lower than
94% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. INSV: -22.76 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
INSV' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -28.2  Med: 3.60 Max: 38.9
Current: -22.76
-28.2
38.9

Analyst Estimate

Dec15 Dec16
Revenue(Mil) 4 6
EPS($) -0.11 -0.09
EPS without NRI($) -0.11 -0.09

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
InSite Vision Inc was incorporated in 1986 as a California Corporation and reincorporated in Delaware in 1987. The Company is an ophthalmic product development company committed to advancing ophthalmic pharmaceutical products to address unmet eye care needs. The Company completed its initial public offering on October 18, 1993. The Company's current portfolio of ophthalmic pharmaceutical products is based on its proprietary DuraSite drug delivery technology. The Company's DuraSite sustained drug delivery technology is a proven, patented synthetic polymer-based formulation designed to extend the residence time of a drug relative to conventional topical therapies. It enables topical delivery of a solution, gel or suspension and could be customized for delivering a variety of potential drug candidates. The Company has focused its research, development and commercial support efforts on the following topical products formulated with its DuraSite drug delivery technology. AzaSite or azithromycin ophthalmic solution 1% is a DuraSite formulation of azithromycin developed as a broad spectrum ocular antibiotic and approved by the U.S. Food and Drug Administration in April 2007 to treat bacterial conjunctivitis. Additional indications are being pursued by Inspire Pharmaceuticals for this product. AzaSite was commercially launched in the United States by Inspire Pharmaceuticals in August 2007. DexaSite is a DuraSite formulation of dexamethasone in development for the treatment of ocular inflammation. In November 2011, it initiated a Phase 3 clinical trial for this product candidate in blepharitis and completed patient enrollment in the clinical trial in September 2012. BromSite is a DuraSite formulation of bromfenac in development for the prevention of post-operative inflammation and eye pain. It initiated a Phase 1/2 clinical trial for this product candidate in August 2010 and received positive top-line results from this study in the first quarter of 2011, which demonstrated the efficacy and safety of BromSite. DuraSite 2 is a next-generation enhanced drug delivery system, which is designed to provide a broad platform for developing superior ophthalmic therapeutics. DuraSite 2 is based on the original DuraSite technology, and incorporates a cationic polymer to achieve sustained and enhanced ocular delivery of drugs. ISV-101 is a DuraSite formulation with a low concentration of bromfenac for the treatment of dry eye disease. The Company is subject to regulation by numerous governmental authorities in the United States and other countries.
» More Articles for INSV

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
QLT Provides Additional Update on Its Proposed Acquisition of InSite Vision Incorporated Sep 04 2015
InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire... Sep 04 2015
Mystery, intrigue as biotech M&A explodes Sep 04 2015
InSite Vision Determines that an Unsolicited Offer from a Global Pharmaceutical Company to Acquire... Sep 04 2015
INSITE VISION INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 04 2015
QLT Provides Further Update on Its Proposed Acquisition of InSite Vision Incorporated Sep 03 2015
INSITE VISION INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 03 2015
InSite Vision Receives Second Unsolicited Acquisition Proposal for $0.35 per Share From a Global... Sep 03 2015
4:12 pm Insite Vision receives a second unsolicited proposal from a global pharmaceutical company... Sep 03 2015
InSite Vision Receives Second Unsolicited Acquisition Proposal for $0.35 per Share From a Global... Sep 03 2015
InSite Vision Announces New Date for Special Stockholder Meeting Sep 02 2015
InSite Vision Announces New Date for Special Stockholder Meeting Sep 02 2015
InSite Vision Named in BromSite Patent Lawsuit; Company Believes Lawsuit Is Without Merit Sep 02 2015
InSite Vision Named in BromSite Patent Lawsuit; Company Believes Lawsuit Is Without Merit Sep 02 2015
INSITE VISION INC Financials Aug 27 2015
INSITE VISION INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... Aug 27 2015
QLT and InSite Vision Agree on Amended and Restated Merger Agreement Aug 27 2015
InSite Vision and QLT Amend Merger Agreement Aug 27 2015
QLT and InSite Vision Agree on Amended and Restated Merger Agreement Aug 27 2015
InSite Vision and QLT Amend Merger Agreement Aug 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK